A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report   more »

During plasmapheresis (plasma exchange, or PE), blood is removed from the patient, and the liquid plasma and the cells are separated by centrifuge. The plasma (including many lymphocytes) is discarded and replaced by normal plasma or human   more »

Autoimmune disease is a condition in which the immune system attacks the body’s own material just as aggressively as it would attack a foreign pathogen. Multiple sclerosis, MS for short, is just one such autoimmune disease, and is one of the most common   more »

Could HDL, the "good cholesterol," have the same protective effect in multiple sclerosis, an inflammatory disease of the brain's white matter, as it does in heart disease, through its anti-inflammatory effects on blood   more »

Women who have multiple sclerosis may reduce their risk of relapses after pregnancy if they breastfeed their babies, according to a study released today that will be presented at the American Academy of Neurology’s   more »

Anti-{alpha}-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Background There is no specific serum-based biomarker for   more »

The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNbeta)-1a in patients with relapsing multiple sclerosis (MS). Further analyses of AFFIRM and SENTINEL data were conducted to determine   more »

Similarities in the onset age of progression in secondary-progressive (SP) and primary-progressive multiple sclerosis (PPMS) have been previously reported. However, with longer follow-up, more relapsing-remitting (RRMS) patients reach SPMS, such   more »

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a wholly-owned subsidiary of the US National Multiple Sclerosis Society, announced a collaborative partnership to evaluate and fund promising multiple sclerosis (MS)   more »

BHT-3009 - Program Overview  

 

 

About BHT-3009 

 

In particular, data from two completed placebo-controlled clinical trials signaled this product candidate’s potential to treat RR-MS patients, with a safety profile similar to placebo. In a Phase II clinical trial, BHT-3009 demonstrated a decrease in brain lesions as measured by magnetic resonance imaging (MRI) in patients who received the 0.5 mg dose. During the follow up period, a trend in the reduction of relapse rates was seen. Results also indicated a tolerizing effect on the immune system as measured by reduction of myelin-specific antibodies in cerebral spinal fluid. In terms of safety, BHT-3009 was well tolerated and patients experienced no significant side effects.

 

 

Current Treatments for MS   

 

Current treatment of MS is threefold, including management of disease progression, relapses, and symptoms. There are currently six therapies approved for use in RR-MS patients in the United States. All of these therapies are non-specific immunomodulatory agents, which reduce the frequency and severity of attacks. Total worldwide 2007 revenue approached $7.2 billion among the drug companies that market FDA-approved RR-MS therapies. Approximately $5.2 billion out of the $7.2 billion total are attributed to sales of interferon beta 1B (Betaseron marketed by Bayer HealthCare Pharmaceuticals Inc.) and interferon beta 1A (sold as Avonex by Biogen Idec Inc.; and as Rebif by EMD Serono, Inc. and Pfizer Inc.). These interferons demonstrate what many consider to be modest efficacy with significant side effects. They also have undesirable administration schedules, ranging from once every other day to once weekly.  In addition to interferons, glatiramer acetate (Copaxone marketed by Teva Neuroscience, Inc. and Sanofi-Aventis SA), is a non-specific immunomodulatory agent approved for RR-MS. It accounts for about $1.7 billion in worldwide sales, requires daily injections and demonstrates efficacy that is generally regarded as similar to the interferons.  

 

Due to unpredictable efficacy and tolerability associated with current therapies, many MS patients receive multiple therapies over the chronic course of disease. Second-line therapies for RR-MS are recommended for patients who inadequately respond to or cannot tolerate other therapies and include natalizumab (Tysabri sold by Biogen Idec Inc. and Elan Corporation, plc) and mitoxantrone (Novantrone marketed by EMD Serono, Inc.). Tysabri, an immune-modulating drug, is delivered intravenously once every four weeks at a registered infusion facility, but carries a risk of serious and sometimes fatal opportunistic infections. Previously removed from the market due to safety concerns, Tysabri has been re-introduced via a restricted distribution program and label. Novantrone, a chemotherapeutic drug used primarily to treat leukemia, is delivered intravenously four times per year in a controlled medical setting. An association with cardiac toxicity, however, means that patients may only receive a limited lifetime dose of Novantrone.

 

Currently, there are no approved therapies directed specifically at reprogramming the immune system by modulating the response of antigen-specific immune cells involved in MS. An antigen-specific product that demonstrates efficacy, presents limited side effects and has a superior administration profile could address a severely unmet medical need in MS.

 

 

About Multiple Sclerosis (MS)

 

MS is a chronic autoimmune disease characterized by the immune system’s attack on specific self-antigens, such as myelin basic protein (MBP) present in the myelin sheath of the central nervous system. This attack on self-antigens leads to the onset of MS, which is characterized by symptoms of numbness, lack of coordination, blindness and paralysis.

 

Clinical data suggests that Bayhill’s lead product candidate BHT-3009 induces the immune system to tolerize to, rather than attack, the MBP in the myelin sheath. BHT-3009 is a plasmid encoding MBP directed specifically at reprogramming the immune system by modulating the response of the antigen-specific immune cells involved in MS. BHT-3009 is being developed to address Relapsing Remitting MS (RR-MS), which is the most common sub-type of MS. RR-MS is characterized by early stage cycles of disease occurrence followed by complete remission, with relapses appearing every one to two years on average.

According to an article published in The New England Journal of Medicine in 2006, MS is the most common non-traumatic cause of disability in young adults in the United States and Europe. According to the National Multiple Sclerosis Society (NMSS) an estimated 400,000 people in the United States have MS, while more than two million people are afflicted worldwide.

 

RR-MS affects 85% of MS patients at onset and 55% of the general MS population at any given time. Most RR-MS patients progress to more debilitating disease within 10 to 25 years. While early-stage RR-MS patients tend to remit to a healthy baseline condition, the chronic nature of disease may result in permanent sensory impairment; visual problems; fatigue; impaired coordination, bladder, bowel and sexual dysfunction; and paralysis.  

 

In addition to RR-MS, there are three other diagnoses of MS:  

-Secondary Progressive (SP) MS: SP-MS begins as RR-MS but slowly worsens into progressive disability that may be associated with superimposed relapses. About 50% of all RR-MS patients progress to SP-MS within 10 years, and 90% within 25 years.  

-Primary Progressive (PP) MS: PP-MS steadily worsens from the time of onset. While there are no detectable relapses, symptoms may periodically improve slightly or stay the same. PP-MS affects about 10% of MS patients and is most common after the age 40.  

-Progressive-Relapsing (PR) MS: PR-MS is progressive from disease onset, but with superimposed relapses. As the least common type, PR-MS affects 5% of MS patients.

 

 

 

Compliments of:

Bayhill Therapeutics

 

Bayhill Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA™ platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases.  Through a targeted and selective approach, the Company’s product candidates are designed to restore the immune system to its normal state, known as “tolerance,” by eliminating specific, harmful immune responses while leaving the  rest of the immune system intact.

 

 

There are no clinical trials for BHT-3009 at this time.

 

In the development of new therapies for multiple sclerosis, there are occasions in which the results of a study surprise investigators and challenge their long-held beliefs about MS. A recent example is the evolving story concerning the development of a drug called rituximab as a treatment for MS, specifically primary   more »

Cognitive impairment is increasingly being recognized as a common and disabling symptom of multiple sclerosis (MS) that contributes to poor quality of life in affected patients. Despite the high prevalence of cognitive impairment in MS, cognitive function is   more »

A drug used to treat multiple sclerosis might make some patients vulnerable to brain infection by reducing the number of immune cells there, researchers at UT Southwestern Medical Center have found. The findings also suggest that the drug, Natalizumab (Tysabri), might be safer and   more »

With more and more people having brain magnetic resonance imaging (MRI) scans for various reasons, doctors are finding people whose scans show signs of multiple sclerosis (MS) even though they have no symptoms of the disease. A study published in the December   more »

A drug called Aricept is currently used to treat memory problems in Alzheimer’s disease. There has been interest in the possible use of Aricept in MS. A recent clinical trial in which 69 individuals with MS participated found that Aricept improved performance on memory tasks.   more »